Guoqing Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guoqing Jin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Jun-Long Zhang
Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P. R. China
4 shared publications - Wenshe Ray Liu
Texas A&M University
3 shared publications - Yingying Ning
Spin‐X Institute School of Chemistry and Chemical Engineering School of Biomedical Sciences and Engineering Guangdong‐Hong Kong‐Macao Joint Laboratory of Optoelectronic and Magnetic Functional Materials State Key Laboratory of Luminescent Materials and Devices South China University of Technology Guangzhou China
3 shared publications - Song Gao
Sun Yat-sen University
2 shared publications Bo Cheng
College of Chemistry and Molecular Engineering Beijing National Laboratory for Molecular Sciences Peking University Beijing 100871 P. R. China
1 shared publication- Calvin V. Chau
Department of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, USA
1 shared publication
Latest Publications
- Open Access
- 3 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A proximity-driven and regioselective peptide bicyclization (PReP-Bicyc) approach for phage display libraries
Peptide macrocyclization is a powerful strategy to enhance the stability, rigidity, binding affinity, and cellular permeability of therapeutic candidates. Peptide bicycles provide superior conformational constraint but remain difficult to generate in phage-displayed libraries because of limited phage-compatible chemistries. Here, we report Proximity-Driven, Regioselective Peptide Bicyclization (PReP-Bicyc), a general, additive-free, phage-compatible strategy for site-selective bicyclization of peptide libraries. PReP-Bicyc uses a rationally designed linker, 4,6-dichloropyrimidine-2-carbonitrile (4,6-DCCPm), that rapidly reacts with an N-terminal cysteine through nitrile-mediated thiazoline formation, followed by proximity-driven intramolecular thiol arylation of two internal cysteines. The resulting bicycles form efficiently under mild conditions while preserving phage viability. Screening a PReP-Bicyc-modified CX4CX4C library against programmed cell death protein 1 (PD-1) identifies sub-micromolar bicyclic ligands (best Kd ≈ 400 nM) that selectively label PD-1-expressing cells and inhibit the PD-1/PD-L1 interaction. PReP-Bicyc provides a robust platform for evolving high-affinity bicyclic ligands and expands the chemical toolkit for macrocyclic therapeutic discovery.
- 3 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA proximity-driven and regioselective peptide bicyclization (PReP-Bicyc) approach for phage display libraries
Peptide macrocyclization is a powerful strategy to enhance the stability, rigidity, binding affinity, and cellular permeability of therapeutic candidates. Peptide bicycles provide superior conformational constraint but remain difficult to generate in phage-displayed libraries because of limited phage-compatible chemistries. Here, we report Proximity-Driven, Regioselective Peptide Bicyclization (PReP-Bicyc), a general, additive-free, phage-compatible strategy for site-selective bicyclization of peptide libraries. PReP-Bicyc uses a rationally designed linker, 4,6-dichloropyrimidine-2-carbonitrile (4,6-DCCPm), that rapidly reacts with an N-terminal cysteine through nitrile-mediated thiazoline formation, followed by proximity-driven intramolecular thiol arylation of two internal cysteines. The resulting bicycles form efficiently under mild conditions while preserving phage viability. Screening a PReP-Bicyc-modified CX4CX4C library against programmed cell death protein 1 (PD-1) identifies sub-micromolar bicyclic ligands (best Kd ≈ 400 nM) that selectively label PD-1-expressing cells and inhibit the PD-1/PD-L1 interaction. PReP-Bicyc provides a robust platform for evolving high-affinity bicyclic ligands and expands the chemical toolkit for macrocyclic therapeutic discovery.
- 2 July 2026
- Published by Elsevier in Trends in Chemistry
- Vol. 8 (8) , 550-552
Rewriting N-terminal cysteine chemistry for peptide-bicycle evolution
- 2 July 2026
- Published by Elsevier in Trends in Chemistry
- Vol. 8 (8) , 550-552
Rewriting N-terminal cysteine chemistry for peptide-bicycle evolution
- 8 April 2026
- Published by Springer Nature in Nature Chemistry
- Vol. 18 (4) , 810
Pyrrolysine refusing to stop
Guoqing Jin and Wenshe Ray Liu retrace how pyrrolysine emerged from a stop codon, challenged the rules of translation, and enabled chemists to encode designer functionalities into proteins.
- 8 April 2026
- Published by Springer Nature in Nature Chemistry
- Vol. 18 (4) , 810
Pyrrolysine refusing to stop
Guoqing Jin and Wenshe Ray Liu retrace how pyrrolysine emerged from a stop codon, challenged the rules of translation, and enabled chemists to encode designer functionalities into proteins.
- Open Access
- 26 September 2025
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 58 (19) , 2985-2996
Advancing Genetically Encoded Lysine (GEK) Chemistry: From Precision Modulation to Therapeutic Innovation
ConspectusGenetically encoded lysine (GEK) chemistry has transformed protein engineering by enabling precise and site-specific modifications, which expand lysine's functional landscape beyond its native post-translational modifications (PTMs). Our work has systematically advanced GEK chemistry by developing engineered pyrrolysyl-tRNA synthetase (PylRS) variants that efficiently incorporate diverse lysine (Lys) derivatives with tailored chemical reactivity. By integrating bioorthogonal handles, acyl and electrophilic warheads, photo-cross-linking groups, and PTM mimics, we have established a set of powerful toolkits for protein labeling, functional studies, and Lys-directed drug design. These advances provide precise control over protein structure and function, facilitating the study of epigenetic modifications, enzyme-substrate interactions, and Lys-guided inhibitor development. As GEK chemistry continues to evolve, its integration with structural/synthetic biology and therapeutic innovation will further expand its impact, unlocking new frontiers in chemical biology and precision therapeutics.
- 26 September 2025
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 58 (19) , 2985-2996
Open AccessAdvancing Genetically Encoded Lysine (GEK) Chemistry: From Precision Modulation to Therapeutic Innovation
ConspectusGenetically encoded lysine (GEK) chemistry has transformed protein engineering by enabling precise and site-specific modifications, which expand lysine's functional landscape beyond its native post-translational modifications (PTMs). Our work has systematically advanced GEK chemistry by developing engineered pyrrolysyl-tRNA synthetase (PylRS) variants that efficiently incorporate diverse lysine (Lys) derivatives with tailored chemical reactivity. By integrating bioorthogonal handles, acyl and electrophilic warheads, photo-cross-linking groups, and PTM mimics, we have established a set of powerful toolkits for protein labeling, functional studies, and Lys-directed drug design. These advances provide precise control over protein structure and function, facilitating the study of epigenetic modifications, enzyme-substrate interactions, and Lys-guided inhibitor development. As GEK chemistry continues to evolve, its integration with structural/synthetic biology and therapeutic innovation will further expand its impact, unlocking new frontiers in chemical biology and precision therapeutics.
- 1 May 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (9) , 1312-1314
Fishing for covalent peptides
- 1 May 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (9) , 1312-1314
Fishing for covalent peptides
- 17 February 2025
- Published by Springer Nature in Nature Reviews Chemistry
- Vol. 9 (3) , 139
Later but better peptide modulations
- 17 February 2025
- Published by Springer Nature in Nature Reviews Chemistry
- Vol. 9 (3) , 139
Later but better peptide modulations
- Open Access
- 17 January 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (8) , 2070-2081
Two birds one stone: β-fluoropyrrolyl-cysteine SNAr chemistry enabling functional porphyrin bioconjugation
This work demonstrates ‘two birds one stone’ β-fluoropyrrolyl-cysteine SNAr chemistry. This methodology not only achieves porphyrin peptide/protein conjugates but also induces attractive porphyrinic photophysical properties to facilitate promising biological applications.
- 17 January 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (8) , 2070-2081
Open AccessTwo birds one stone: β-fluoropyrrolyl-cysteine SNAr chemistry enabling functional porphyrin bioconjugation
This work demonstrates ‘two birds one stone’ β-fluoropyrrolyl-cysteine SNAr chemistry. This methodology not only achieves porphyrin peptide/protein conjugates but also induces attractive porphyrinic photophysical properties to facilitate promising biological applications.
- Open Access
- 30 September 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (43)
Innenrücktitelbild: Bioorthogonal Lanthanide Molecular Probes for Near‐Infrared Fluorescence and Mass Spectrometry Imaging (Angew. Chem. 43/2022)
- 30 September 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (43)
Open AccessInnenrücktitelbild: Bioorthogonal Lanthanide Molecular Probes for Near‐Infrared Fluorescence and Mass Spectrometry Imaging (Angew. Chem. 43/2022)
- 6 July 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 51 (14) , 6177-6209
Lanthanide porphyrinoids as molecular theranostics
This Review summarises the history and the ‘state-of-the-art’ development of lanthanide (Ln) porphyrinoids as theranostic agents. Applications such as near-infrared (NIR) fluorescence imaging (FL), magnetic resonance imaging (MRI), radiotherapy, chemotherapy and phototheranostics will be discussed.
- 6 July 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 51 (14) , 6177-6209
Lanthanide porphyrinoids as molecular theranostics
This Review summarises the history and the ‘state-of-the-art’ development of lanthanide (Ln) porphyrinoids as theranostic agents. Applications such as near-infrared (NIR) fluorescence imaging (FL), magnetic resonance imaging (MRI), radiotherapy, chemotherapy and phototheranostics will be discussed.
- 5 April 2022
- Published by Wiley in Chemistry – An Asian Journal
- Vol. 17 (10) , e202200181
Gadolinium(III) Porphyrinoid Phototheranostics
Molecular phototheranostics as an emerging field of modern precision medicine has recently attracted increasing research attention owing to non‐invasiveness, high precision, and controllable nature of light. In this work, we reported promising gadolinium (Gd3+) porphyrinoids as phototheranostic agents for magnetic resonance imaging (MRI) and photodynamic therapy (PDT). The synthesized Gd‐1‐4‐Glu featured with meso‐glycosylation and β‐lactonization to endow good biocompatibility and improved photophysical properties. In particular, β‐lactonization of glycosylated Gd3+ porphyrinoids substantially red‐shifted Q band absorption to near‐infrared (NIR) region and boosted generation of reactive oxygen species including 1O2, and some radical species that engaged in both type II and type I PDT pathways. In addition, the number and regioisomerism of β‐oxazolone moieties was observed to play an essential role in improving longitude relaxivity (r1) of Gd‐1‐4‐Glu of up to 4.3±0.2 mM−1s−1 by affecting environmental water exchange. Taking Gd‐4‐Glu as a promising complex, we further achieved real‐time T1‐weighted MRI and PDT on HeLa tumour mice in vivo, revealing the appealing potential of Gd3+ porphyrinoids in phototheranostics.
- 5 April 2022
- Published by Wiley in Chemistry – An Asian Journal
- Vol. 17 (10) , e202200181
Gadolinium(III) Porphyrinoid Phototheranostics
Molecular phototheranostics as an emerging field of modern precision medicine has recently attracted increasing research attention owing to non‐invasiveness, high precision, and controllable nature of light. In this work, we reported promising gadolinium (Gd3+) porphyrinoids as phototheranostic agents for magnetic resonance imaging (MRI) and photodynamic therapy (PDT). The synthesized Gd‐1‐4‐Glu featured with meso‐glycosylation and β‐lactonization to endow good biocompatibility and improved photophysical properties. In particular, β‐lactonization of glycosylated Gd3+ porphyrinoids substantially red‐shifted Q band absorption to near‐infrared (NIR) region and boosted generation of reactive oxygen species including 1O2, and some radical species that engaged in both type II and type I PDT pathways. In addition, the number and regioisomerism of β‐oxazolone moieties was observed to play an essential role in improving longitude relaxivity (r1) of Gd‐1‐4‐Glu of up to 4.3±0.2 mM−1s−1 by affecting environmental water exchange. Taking Gd‐4‐Glu as a promising complex, we further achieved real‐time T1‐weighted MRI and PDT on HeLa tumour mice in vivo, revealing the appealing potential of Gd3+ porphyrinoids in phototheranostics.